• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review.

作者信息

Pasupulati Saphal Lakshmi, Srinivasa Rao Katiboina, Sharma Sushil, Madhavrao C, Rangari Gaurav, Misra Arup Kumar, Kutikuppala L V Simhachalam, Devika T, Sarikonda Sandhya Rani

机构信息

Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India.

Department of Pharmacology, Guntur Medical College, Guntur, Andhra Pradesh, India.

出版信息

Cancer Chemother Pharmacol. 2025 Sep 16;95(1):87. doi: 10.1007/s00280-025-04810-8.

DOI:10.1007/s00280-025-04810-8
PMID:40956449
Abstract
摘要

相似文献

1
Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review.他拉唑帕利的临床药理学与治疗应用：一项全面综述
Cancer Chemother Pharmacol. 2025 Sep 16;95(1):87. doi: 10.1007/s00280-025-04810-8.
2
Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents.他拉唑帕利及其衍生物作为PARP-1靶向剂的放射性合成与评价
Biomedicines. 2021 May 18;9(5):565. doi: 10.3390/biomedicines9050565.
3
Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis.PARP 抑制剂治疗前列腺癌的疗效和安全性：系统评价和网络荟萃分析。
Chin Clin Oncol. 2024 Aug;13(4):64. doi: 10.21037/cco-24-82.
4
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.一项关于间歇性他拉唑帕利联合替莫唑胺治疗转移性去势抵抗性前列腺癌且DNA损伤反应基因无突变患者的1b/2期研究。
Invest New Drugs. 2025 Sep 4. doi: 10.1007/s10637-025-01580-1.
5
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.聚（ADP - 核糖）聚合酶（PARP）抑制剂他拉唑帕尼与呼肠孤病毒协同作用，在小鼠模型体内诱导癌症杀伤和肿瘤控制。
Nat Commun. 2025 Jul 8;16(1):6299. doi: 10.1038/s41467-025-61297-w.
6
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.一项关于gedatolisib联合他拉唑帕尼治疗晚期三阴性或BRCA1/2阳性、HER2阴性乳腺癌的I/II期试验。
Breast Cancer Res Treat. 2025 Jun 5. doi: 10.1007/s10549-025-07747-x.
7
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis.已批准的 PARP 抑制剂在癌症中的安全性和耐受性比较：系统评价和网络荟萃分析。
Pharmacol Res. 2021 Oct;172:105808. doi: 10.1016/j.phrs.2021.105808. Epub 2021 Aug 11.
8
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.他拉唑帕利联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌男性患者：随机、安慰剂对照3期TALAPRO-2试验的最终总生存结果
Lancet. 2025 Jul 16. doi: 10.1016/S0140-6736(25)00684-1.
9
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.他拉唑帕利联合恩杂鲁胺治疗同源重组修复缺陷的转移性去势抵抗性前列腺癌男性患者：随机、安慰剂对照3期TALAPRO-2试验的最终总生存结果
Lancet. 2025 Jul 16. doi: 10.1016/S0140-6736(25)00683-X.
10
Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy.同源修复缺陷型胰腺癌：精准靶向DNA损伤反应是一种有效的治疗策略。
United European Gastroenterol J. 2025 Aug 18. doi: 10.1002/ueg2.12773.

本文引用的文献

1
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.一线 talazoparib 联合恩扎卢胺治疗 HRR 缺陷转移性去势抵抗性前列腺癌：III 期 TALAPRO-2 试验。
Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4.
2
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.PARP 抑制剂：药理学、药代动力学和药物遗传学综述。
Semin Oncol. 2024 Feb-Apr;51(1-2):19-24. doi: 10.1053/j.seminoncol.2023.09.005. Epub 2023 Oct 14.
3
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
肿瘤治疗中的 PARP 抑制剂的药代动力学和药效动力学。
Clin Pharmacokinet. 2022 Dec;61(12):1649-1675. doi: 10.1007/s40262-022-01167-6. Epub 2022 Oct 11.
4
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.他拉唑帕尼，一种聚（ADP-核糖）聚合酶抑制剂，用于转移性去势抵抗性前列腺癌和 DNA 损伤反应改变：TALAPRO-1 安全性分析。
Oncologist. 2022 Oct 1;27(10):e783-e795. doi: 10.1093/oncolo/oyac172.
5
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.接受他拉唑帕尼治疗的携带DNA损伤反应改变的转移性去势抵抗性前列腺癌男性患者的患者报告结局：TALAPRO-1研究结果
Eur Urol. 2023 Apr;83(4):352-360. doi: 10.1016/j.eururo.2022.05.030. Epub 2022 Jun 22.
6
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.同源重组缺陷：概念、定义和检测。
Oncologist. 2022 Mar 11;27(3):167-174. doi: 10.1093/oncolo/oyab053.
7
Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.评价不同程度肝损伤的晚期癌症患者中使用他拉唑帕尼的药代动力学和安全性。
Br J Clin Pharmacol. 2022 Jul;88(7):3392-3403. doi: 10.1111/bcp.15294. Epub 2022 Mar 18.
8
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.复发/难治性急性髓系白血病中 DNA 甲基转移酶抑制剂地西他滨和 PARP 抑制剂他拉唑帕利联合治疗的 I 期临床试验。
Clin Cancer Res. 2022 Apr 1;28(7):1313-1322. doi: 10.1158/1078-0432.CCR-21-3729.
9
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.泰拉唑帕利联合恩扎卢胺治疗转移性去势抵抗性前列腺癌：TALAPRO-2 期 III 期研究设计。
Future Oncol. 2022 Feb;18(4):425-436. doi: 10.2217/fon-2021-0811. Epub 2022 Jan 26.
10
Veliparib for the treatment of solid malignancies.维利帕尼用于实体恶性肿瘤的治疗。
J Oncol Pharm Pract. 2022 Jun;28(4):924-934. doi: 10.1177/10781552221073990. Epub 2022 Jan 17.